MHC vs. NCYT, POLX, IHC, AVO, RUA, SUN, BELL, DEMG, NIOX, and SN
Should you be buying MyHealthChecked stock or one of its competitors? The main competitors of MyHealthChecked include Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), Belluscura (BELL), Deltex Medical Group (DEMG), NIOX Group (NIOX), and Smith & Nephew (SN). These companies are all part of the "medical devices" industry.
MyHealthChecked vs.
Novacyt (LON:NCYT) and MyHealthChecked (LON:MHC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, community ranking, media sentiment, dividends, profitability and analyst recommendations.
MyHealthChecked has lower revenue, but higher earnings than Novacyt. MyHealthChecked is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.
Novacyt received 36 more outperform votes than MyHealthChecked when rated by MarketBeat users.
In the previous week, Novacyt had 2 more articles in the media than MyHealthChecked. MarketBeat recorded 2 mentions for Novacyt and 0 mentions for MyHealthChecked. MyHealthChecked's average media sentiment score of 0.00 beat Novacyt's score of -0.30 indicating that MyHealthChecked is being referred to more favorably in the news media.
0.1% of Novacyt shares are held by institutional investors. Comparatively, 3.1% of MyHealthChecked shares are held by institutional investors. 3.1% of Novacyt shares are held by insiders. Comparatively, 53.6% of MyHealthChecked shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
MyHealthChecked has a net margin of -11.06% compared to Novacyt's net margin of -203.06%. MyHealthChecked's return on equity of -12.80% beat Novacyt's return on equity.
Novacyt has a beta of -1.86, indicating that its share price is 286% less volatile than the S&P 500. Comparatively, MyHealthChecked has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500.
Summary
MyHealthChecked beats Novacyt on 9 of the 14 factors compared between the two stocks.
Get MyHealthChecked News Delivered to You Automatically
Sign up to receive the latest news and ratings for MHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MyHealthChecked Competitors List
Related Companies and Tools
This page (LON:MHC) was last updated on 3/19/2025 by MarketBeat.com Staff
